• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Sunday 04/22/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

biotechnology

  • 2:52 PM

    Proceeds To Fund Commercialization of First Approved Drug and Pivotal Clinical Programs in 2018   NEW YORK, January 30, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO) (“Q BioMed” or the “Company”), a commercial stage biotechnology acceleration development company is pleased to announce pricing of a public offering of an aggregate of 1,711,875 shares of common stock of the Company, together with warrants to purchase up to 1,711,875 shares of common stock of the Company, at a public offering price of $3.20 per share

    Read more
  • 11:18 AM

    LOS ANGELES, January 23, 2018 /PRNewswire/ — GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris: GTBP.PA) today announced that it has entered into definitive agreements for a private placement of convertible notes and warrants for gross proceeds of $7,055,000. The company intends to use the proceeds from the financing to advance its immuno-oncology programs, which are based on the company’s proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms, neurology (CNS) pipeline progress, and for

    Read more
  • 12:17 PM

    Aug 01, 2017, ETST, OTC Disclosure & News Service – Hollywood, FL, Aug. 01, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotechnology company that operates in the fields of hemp cannabinoid, nutraceutical, pharmaceutical, and medical device research and development, announces that it has signed an agreement with the Centre de Développement Bioalimentaire du Québec (CDBQ), a major force in the agro-food industry in Canada. CDBQ to take ETST products from

    Read more
  • 9:00 AM

    VANCOUVER, Washington, May 17, 2017, CYDY, (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, announces the treatment of the first patient in its Phase 2 clinical trial for Graft versus Host Disease (GvHD), its leading immunologic indication for PRO 140. GvHD is a potentially life-threatening complication in patients requiring a bone marrow transplant because their immune systems have been depleted during aggressive cancer therapy for

    Read more
  • 4:00 PM

    BOTHELL, WA and ATLANTA, GA–(Marketwired – Apr 24, 2017) – On April 20, 2017, Cocrystal Pharma, Inc. (OTCQB: COCP) (the “Company”) closed on proceeds of $3,000,000 in a private placement offering (the “Offering”) of 12,500,000 shares of the Company’s common stock at a purchase price of $0.24 per share. The purchasers included one of the members of the Company’s board of directors, Chairman Dr. Raymond F. Schinazi. In addition, OPKO Health, Inc. invested in the Offering, of which the Company’s

    Read more
  • 9:32 AM

    ORLANDO, Fla., March 17, 2017, IMUN, (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal™, its proprietary formulation of lower-dose naltrexone, announced today that the Dominican Republic Ministry of Public Health has granted Immune’s request to export Lodonal to Kenya. Immune Therapeutics formulates and manufactures Lodonal in the Dominican Republic. Local laws require a Certificate of Pharmaceutical Product (“COPP”) to export Lodonal to Kenya. “The granting of our export

    Read more
Public Wire Banner